Lilly's Cymbalta gets closer to FDA approval

One year after receiving its first conditional approval for its experimental depression medicine, Cymbalta, Eli Lilly said Wednesday it received a second notice from the FDA saying the company does not need to conduct more clinical trials to get approval. However, Lilly still must resolve issues with its plant where Cymbalta will be made.

View Full Article in:

MSNBC · Wall Street Journal (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Compliance and Ethics Director
Sysmex America, Inc.
Lincolnshire, IL
Director, Site Quality Management
Palm Springs, CA
Compliance Officer-Medical Products
W. L. Gore
Flagstaff, AZ
Project Manager RA - 15000003MD
Santa Clara, CA
Director, Site Quality Management
Minneapolis, MN